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Blood Transfusion Reactions
John Ayodele Olaniyi
Abstract
Blood transfusion reaction/adverse transfusion reactions could be fatal/severe or 
mild, immediate or delayed, immunological or nonimmunological, and infectious 
or noninfectious, and attention is paid particularly to the incidence, possible causes 
and pathophysiology, clinical features, and management of each type with the 
aim of improving awareness and raising consciousness towards improving blood 
safety and judicious use of blood so as to forestall these blood transfusion reactions 
as much as possible. This chapter serves as a synopsis to adverse blood reactions, 
which are very common but apparently more often under-recognized and/or under-
reported particularly in developing countries. This should sharpen the conscious-
ness of all health practitioners involved in blood transfusion services towards taking 
measures at preventing transfusion reactions right from donor selection up to the 
infusion of blood into the recipients.
Keywords: adverse blood reactions, blood safety, judicious use of blood,  
clinical features, management, immunological, immediate, infectious
1. Introduction
Blood transfusion remains a life-saving therapy and according to World Health 
Organization (WHO) guidelines, of 10 units per 1000 population, approximately 
8 million units of blood are currently needed to meet the transfusion demand for a 
population of about 800 million [1]. While in the industrialized world, blood provi-
sion and blood safety are well established, in Africa, there is limited access to blood, 
and provision of unsafe blood renders blood safety a major public health concern. 
Blood transfusion may be needed in circumstances like obstetric hemorrhage, road 
traffic accidents, armed conflicts, sickle cell disease, anaemias especially in chil-
dren, malnutrition, HIV, malaria, and parasitic infections. It is therefore important 
to always highlight the blood transfusion reactions, possible causes, expected 
symptoms and signs, preventive measures, and appropriate management. This will 
further encourage judicious use of blood and blood components.
2. What is blood transfusion reaction?
Blood transfusion reaction refers to undesirable, unintended, adverse response 
to the administration of blood, blood components, or derivatives that are well 
thought-out to be definitely probable or possibly related to this product. About 
0.5–3% of all transfusions result in transfusion reaction.
Blood transfusion reactions can basically be categorized as infectious or 
noninfectious. The majority of blood transfusion reactions are, nonetheless, 
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noninfectious with outcomes ranging from nonsignificant consequences to death 
[2, 3]. However, the infectious effects are given more prominence than other 
adverse reactions.
For emphasis, when any unexpected or untoward symptom or sign occurs 
during or shortly after the transfusion of a blood component, a transfusion reaction 
must be considered as the precipitating event until confirmed otherwise [4].
3. Classification and incidence of adverse events
Broadly, BTR can be classified as infectious or noninfectious, immunological 
or nonimmunological, immediate or delayed, and mild or life threatening. The 
common, well known manifestations to all types of BTR include fever, chills, and 
urticaria [3, 5, 6] (Table 1).
3.1 The acute (life-threatening) BTRs
• Acute (immediate) haemolytic transfusion reaction
• Delayed haemolytic transfusion reaction
• Transfusion transmitted bacterial infection
• Anaphylaxis
• Transfusion-related acute lung injury (TRALI)
• Transfusion-associated circulatory overload (TACO)
3.1.1 Other acute noninfectious complications of blood transfusion
• Allergic reactions
• Anaphylaxis (IgA-deficient recipient)
• Lung damage from microaggregates (massive transfusion)
• Transfusion-associated circulatory overload (“TACO”)
• Bacterial infection (mainly with platelet transfusion)
• Hypothermia (rapid infusion of refrigerated blood)
• Citrate toxicity/hypocalcemia (massive transfusion or apheresis)
• Graft-versus-host disease
• Air embolism
3.1.2 Classification of transfusion reactions based on immune or nonimmune
• Acute immunological (<24 hours)
 ○ Immediate (acute) haemolytic transfusion reaction
 ○ Febrile nonhemolytic.
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 ○ Minor/major allergic.
 ○ Anaphylaxis.
 ○ TRALI.
 ○ Acute nonimmunological (<24 hours).
 ○ Bacterial contamination.
 ○ Transfusion-associated circulatory overload (TACO).
• Delayed immunological (>24 hours).
 ○ Delayed haemolytic transfusion reaction.
 ○ Other delayed reactions.
 ○ Minor/major allergic.
 ○ Anaphylaxis.
• Delayed nonimmunological (>24 hours).
 ○ Transfusion transmissible infections (TTIs) (HIV/HBV/HCV).
 ○ Transfusion-associated circulatory overload (TACO).
Tables 1, 3 and 5 refer to classification of BTRs.
Acute transfusion reactions Delayed transfusion reactions
Acute haemolytic reaction (AHTR) Delayed haemolytic reaction
Anaphylaxis Transfusion transmitted infection
Bacterial contamination of blood component Transfusion-associated graft-versus-host disease
Transfusion-associated acute long injury Post-transfusion purpura
Transfusion-associated circulatory overload (TACO) Iron overload
Allergic reaction Immunosuppression
Febrile nonhemolytic transfusion reaction 
(FNHTR)
Table 1. 
Types of blood transfusion reactions.
Adverse events Risk/unit
Mild allergic 1 in 100
FNH 1 in 300
TACO 1 in 700
TRALI 1 in 10,000
Bacteria contamination 1 in 10,000
Anaphylactic 1 in 40,000
Fatal haemolytic 1 in 1,000,000
HIV/HBV/HCV 1 in 1,000,000 to 8,000,000
Table 2. 
Frequency of transfusion reactions.
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3.2 Frequency of transfusion reactions
The risk per unit for each adverse event is as stated in Table 2.
4. Common signs and symptoms of blood transfusion
Although the signs and symptoms of BTR will be fully discussed under each 
type of blood transfusion reaction, it is important that these features be highlighted 
as it relates to each system.
i. Circulatory: circulatory changes include changes in blood pressure, tachycar-
dia, arrhythmia, bleeding, blood in urine, and increase in bleeding tendencies.
ii. Pulmonary: pulmonary features include shortness of breath, dyspnea, 
wheezing, cough, and changes on chest X-ray.
iii. Immune: itching, rash/hives, flushing, fever, and chills/rigors.
iv. Others: Unexplained discomfort, back pain, chest pain, pain at the site of 
intravenous infusion and along the course of the vein, and anxiety.
4.1 Recognition at bedside
The complex background clinical condition of critically ill patients could mask 
the symptoms of a serious blood transfusion reaction; therefore, ventilated patients 
could have increased peak airway pressures, hyperthermia, and changes in urine 
output or color in the context of a blood transfusion, during a massive transfusion 
protocol. Therefore, monitoring core temperature, prompt use of measures to 
avoid hypothermia, using blood warmers, watch for hypocalcaemia, acidosis, and 
hyperkalemia go a long way in unmasking blood transfusion reactions.
5. Types of transfusion reactions
5.1 Minor transfusion reaction symptoms
A BTR is regarded as minor if:
• The hives or rash cover less than 25% of the body and there are no other 
symptoms.
• The fever (1°C rise over baseline and higher than 38°C) is associated with no 
other symptoms.
Quick steps to take when temperature increases by >1°C and >38°C (Table 3)
• Stop transfusion
• Clerical check
• Notify physician
• Notify blood bank
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If clerical error is established or additional serious symptoms are identified, do 
not order for restart of blood transfusion. Instead
• Administer acetaminophen 325 mg
• Continue to monitor patient carefully and frequently
• Stop transfusion if symptoms worsen or additional symptoms develop
• If uneventful, complete transfusion reaction investigation form
• Send to blood bank with blood sample as per algorithm
Suspect
• Hemolytic transfusion reaction
• Bacterial contamination
Initiate transfusion reaction if the abovementioned points are excluded in 
investigation by
• Completing form 3.
• Collecting blood samples
• Sending blood bag to blood bank
• Continuing to monitor patient
• Reporting the condition to physician
The predominant symptom of a fever is most commonly seen in:
• Acute hemolytic transfusion reactions (AHTR)
• Febrile nonhemolytic transfusion reactions (FNHTR)
• Bacterial sepsis or contamination
5.2 Febrile nonhemolytic transfusion reaction (FNHTR)
The incidence of FNHTR is 1 in 300 for RBC concentrate transfusion and 1 in 20 
for platelet concentrate transfusion.
Pathophysiological FNHTRs develop in patients that already have anti-leukocyte 
antibodies. Anti-leukocyte antibodies are raised in multiply transfused patients and 
multiparous women usually following RBC or platelet transfusions. In addition, 
donor-derived leukocytes present in platelets and RBC products liberate cytokines 
in the course of storage of blood and may also mediate NHTRs. Such cytokines 
include IL1, IL6, IL8, and TNF. Therefore, pre-storage leukoreduction may reduce 
the accumulation of these biologic mediators and the incidence of febrile, hypoten-
sive, or hypoxic transfusion reactions.
Blood Groups
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Clinical presentation: fever during transfusion or up to 4 hours after. The patient 
may also experience chills, rigors, nausea and vomiting, and hypotension without 
fever. FNHTRs typically manifest during or within 4 hours of transfusion with fever 
(defined as an increase in temperature of 1°C above the patient’s baseline tempera-
ture, typically to 38°C) with or without chills and/or rigors. Such reactions may also 
manifest primarily with chills and/or rigors with minimal or absent febrile compo-
nent particularly in patients receiving antipyretics. Symptoms are self-limited and 
respond to symptomatic treatment, which includes antipyretics for fever and chills 
and meperidine for rigors. Close differentials to FNHTRs include acute haemolytic 
transfusion reaction and septic transfusion reactions and patients’ underlying medical 
condition. Therefore, it is important to do necessary investigations to rule out hae-
molysis. Leukoreduction has been associated with significant reduction in FNHTRs.
Management: blood transfusion should be stopped immediately and the order-
ing physician should be informed. Blood transfusion may be restarted cautiously as 
directed after the thorough investigation (Table 3 and Algorithm 1).
5.3 Acute haemolytic transfusion reaction (AHTR)
The incidence of AHTR is 1 in 38,000. It is caused by transfusion of incompat-
ible ABO blood group to a patient. It can be fatal with a mortality rate of about 10% 
and the risk of death is directly proportional to the amount of incompatible blood 
transfused.
Clinical presentation: fever and chills happen to be the most common feature. 
Anxiety, pain at the site of infusion, nausea/vomiting, back pain, dyspnea, flush-
ing, wheezing and passage of red color urine, haemoglobinuria, hypotension, renal 
failure, disseminated intravascular coagulation (DIC), and shock may occur as late/
terminal complications.
Check for haemolysis
Perform visual examination of patient’s plasma and urine (plasma and urine hemoglobin can be checked but 
this is not essential).
Blood film may show spherocytosis.
Bilirubin and lactate dehydrogenase (LDH) levels will be raised.
Check for incompatibility
Check the documentation and the patient’s identity.
Repeat ABO group of patient pre-transfusion and post-transfusion and of the donor unit(s).
Screen the patient for red cell antibodies pre-transfusion and post-transfusion
Repeat crossmatch with pre-transfusion and post-transfusion samples.
Direct antiglobulin test (DAT) on pre- and post-transfusion samples.
Eluate from patient’s red cells.
Check for disseminated intravascular coagulation
Perform blood count and film, coagulation screen, and fibrin degradation products (or D-dimers).
Check for renal dysfunction
Check blood urea, creatinine, and electrolytes.
Check for bacterial infection
Take blood cultures from the patient and donor unit including immediate Gram stain.
Immunological investigations
Check immunoglobulin A (IgA) levels and anti-IgA antibodies.
Table 3. 
Investigations indicated in transfusion reactions.
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Pathophysiology: the ABO isohemagglutinins are compliment fixing and lead 
to intravascular destruction of transfused red cells which can manifest as hemo-
globinemia and haemoglobinuria. Often, fever is the only initial sign. Activation 
of compliments leads to the release of cytokines like tumor necrosis factor, which 
is responsible for the fever and chills. The serologic hallmark of acute haemolytic 
reaction is a positive direct antiglobulin test (DAT), which demonstrates both IgG 
and compliment on the surface of recipient circulating red cells. Disseminated 
intravascular coagulation also occurs and bleeding may result.
Possible sources of error/causes include patient misidentification due to cleri-
cal error or failure to follow established hospital procedures. Therefore, definitive 
bedside patient identification, both at the time type and screening specimen, is 
being obtained, and the time the product is to be administered is very crucial. It 
has been advocated that the risk of mistransfusion can be greatly reduced by using 
barcode and radiofrequency chip technologies in order to ensure correct patient 
identification.
Also, AHTR can occur after platelet transfusions, typically involving a group A 
patient receiving group O platelets that contain high titer anti-A antibody.
Management: the treatment of AHTR is mainly supportive and it includes taking 
the following steps:
• STOP the transfusion!
• Check if any clerical errors in identifying the patient, blood group, and 
product label
• Notify the practitioner and blood bank, return product, and recollect sample 
from patient to confirm blood group
Algorithm 1. 
Algorithm to follow in investigating acute transfusion reaction.
Blood Groups
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• Monitor patient closely
• Institute fluids and vaso-pressures for hypotension and urinary output.
5.4 Bacterial sepsis or contamination
The incidence of bacterial contamination for RBC is 1 in 50,000, 1 in 250,000 
symptomatic septic reactions, and 1 in 500,000 with fatal bacterial sepsis. The 
incidence of bacterial contamination for platelet is 1 in 1000 with 1 in 10,000 
symptomatic septic reactions and 1 in 60,000 fatal bacterial sepsis. About 10% of 
transfusion-related deaths are associated with bacterial sepsis.
Clinical presentation: the clinical features are similar to that of AHTRs and 
comprises of chills, rigors, high grade fever, tachycardia, hypotension, nausea, and 
vomiting. Disseminated intravascular coagulation (DIC) and shock may occur. 
Close examination of blood bag may reveal clots and change in color of blood in 
the bag compared to blood in the segmented tubing. There is no obvious focus of 
infection in the patient. The reaction typically develops 9–24 hours post transfusion 
and usually in neutropenic patients.
Management: such blood transfusion should be discontinued, if suspected and a 
doctor should be notified immediately who will notify and return the product to the 
blood bank after careful documentation of events. Necessary investigations should 
be carried out notably and blood culture samples should be collected. All neces-
sary supportive interventions should be applied as dictated by the patient’s clinical 
condition and the patient should be closely monitored. Also, abnormal bleeding 
or oozing in a patient during surgery that is equally having blood transfusion may 
raise suspicion of acute haemolytic transfusion reaction with DIC and appropriate 
management should be promptly applied (Algorithm 2).
5.5 Delayed haemolytic transfusion reaction (DHTRs)
In DHTRs, the patients develop an alloantibody to an RBC antigen following 
previous transfusion, pregnancy, or HSCT. Such red blood cell alloantibodies may 
decrease in titer although remaining clinically important, and hence, the patient has 
apparently negative antibody screening because the titer of the antibody has fallen 
below the detectable limit. In the event of a subsequent transfusion, the patient 
develops an anamnestic immune response to the mismatched antigen leading to 
delayed antibody-mediated destruction of transfused RBCs.
Clinical manifestation of AHTRs occurs 5–15 days post transfusion and it com-
prises haemoglobinuria, jaundice, and pallor as a result of the acute haemolytic 
process. In the context of a sickle cell disease patient (SCD) that often receives blood 
transfusion because of hyper-haemolytic crises, these features of haemolytic transfu-
sion reaction are often accompanied by features of vaso-occlusive crisis (VOC), that 
is, pain, fever, and acute chest syndrome. There is usually worsened anemia and 
reticulocytopenia. In fact, DHTR is often misdiagnosed as VOC in SCD patient and 
the patient is unduly further transfused which culminates in multi-organ failure [5–9].
When features of AHTRs manifest, the link to the preceding transfusion is not 
always obvious. Direct antiglobulin test (DAT) is often positive for IgG, with or 
without compliment, depending on the antibody if carried out at this point. Also, 
an eluate may be performed to remove the IgG coating the circulating RBCs in order 
to identify it because a positive DAT may be unspecific. The antibody screen may 
also demonstrate the presence of a new antibody, although this may lag behind a 
positive DAT by a few days. The haemolysis in DHTRs is IgG mediated and thus 
extravascular; however, it is noteworthy that alloantibodies to Kidd blood group 
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antigens may fix compliment and cause intravascular haemolysis with consequent 
haemoglobinuria, and occasional instances of severe complications like acute renal 
failure or disseminated intravascular coagulation have been reported. The antibod-
ies most often implicated in DHTRs are directed against antigens in the Rh (34%), 
Kidd (30%), Duffy (14%), Kell (13%), and MNSs (4%) [8, 10]
5.5.1 Management of DHTRs
Ensure leukocyte-poor products as a preventive measure (refer Algorithm 2).
5.6 Transfusion-related acute lung injury (TRALI)
A consensus definition of TRALI is acute lung injury (ALL) occurring during a 
transfusion or within 6 hours of completing a transfusion with no other temporarily 
associated causes of acute lung injury (ALL). ALL is defined as (i) a syndrome of 10 
acute onsets, (ii) hypoxemia (PaO2/FiO2 < 300 mm of Hg, O2 saturation < 90% on 
room air or other clinical evidence), (iii) bilateral pulmonary infiltrates, and (iv) 
no evidence of circulatory overload [7, 11].
The development of TRALI, which is a potentially life-threatening reaction, is 
triggered by passive transfusion of donor anti-granulocyte antibodies (anti-HLA 
or anti HNA antibodies), cytokines, biologically active lipids, or other substances 
into the recipient. These cause acute lung injury with noncardiogenic pulmonary 
edema. The signs and symptoms comprise dyspnea, hypoxemia, hypotension, 
fever, and a chest X-ray showing bilateral lung infiltrates with pulmonary edema 
(Figure 1) [7, 11].
Algorithm 2. 
Necessary steps in the management of blood transfusion reactions.
Blood Groups
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Management: aggressive pulmonary support including mechanical ventila-
tion is frequently required. Approximately 80% of patients improve within 
48–96 hours and all the patients require oxygen support with approximately 
70% needing mechanical ventilation. Infrequently, antibodies in the recipient 
may react with donor granulocytes that were present in units of RBCs or platelets 
transfused. Strangely, in some cases of TRALI, neither recipient nor donor-
derived antibodies can be identified. Other mechanisms have been advanced such 
as the priming of neutrophils by bioactive lipids that accumulate during blood 
storage (Figure 2) [7, 11].
The United States FDA in 2007 documented that TRALI represented 65% of all 
transfusion-related fatalities. The widespread implementation of TRALI risk reduc-
tion strategies adopted thereafter led to reduction to 37% of transfusion fatalities 
reported in the 5-year period from 2008 to 2012. TRALI remains the leading cause 
of death due to transfusion in the US.
The probable incidence rate of TRALI is about 1/5000 transfusions of plasma 
containing blood product, that is, RBCs, platelets, concentrate, platelet apheresis 
units, and plasma with a 5–10% fatality rate. TRALI may be difficult to differentiate 
from manifestations of patients underlying medical problems particularly those 
of cardiac origin, such as congestive heart failure and fluid overload brought on by 
transfusion.
Clinical management is supportive with the goal of reversing progressive 
hypoxemia. There is no universal method to prevent TRALI. Once blood from a 
particular patient is implicated in a case of TRALI, the donor is excluded from the 
donor pool. Preventing the first case of TRALI by those donors, however, requires 
the elimination of all blood donors whose plasma contain anti-HLA or anti-
neutrophil antibodies. For plasma, this is achieved by excluding female donors from 
the plasma donor pool because multiparous females are most likely among a healthy 
donor population to have anti-HLA antibodies as a result of sensitization during 
pregnancy [7, 11]
When this approach was adopted in the UK in late 2003, where 60% of TRALI 
had been caused by plasma transfusions, no report of TRALI death due to plasma 
occurred after 2004 (6 deaths occurred in 2005, none from plasma). Major blood 
suppliers in the US now limit the use of female plasma or screen for HLA or HNA 
antibodies in multiparous donors. Even with these precautions in place, cases of 
TRALI in which HLA or any other granulocyte-specific antibodies do not appear to 
be responsible will not be eliminated.
Figure 1. 
CXR of a TRALI patient showing pulmonary infiltrates. 
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Therefore, strict transfusion criteria for plasma-rich blood products, early 
recognition, and prompt clinical management are the keys to dealing with these 
potentially fatal transfusion reactions.
Reporting suspected cases of TRALI to the blood bank is also important in 
limiting potential risk to other patients by quarantine of any co-components from 
the same donation and evaluating the donor with possible exclusion from future 
donation if TRALI is confirmed [7, 11].
5.7 Transfusion-associated circulatory overload (TACO)
The incidence of TACO is 1/100 and the risk factors in TACO include patients 
with limited cardiopulmonary reserve, that is, the very young and the very old, high 
volume transfusion, background renal, or cardiac disease.
The onset is usually 1–2 hours post transfusion. TACO manifests as shortness of 
breath, cough, chest tightness, cyanosis, rales, orthopnea tachycardia, distended 
jugular veins, S3 gallop, and pulmonary edema, which are consistent with cardiac 
decompensation following volume overload [7, 12].
It is important that the vital signs of a patient under general anesthesia and 
on blood transfusion be continually monitored in order to be able to detect these 
features early and to be able to prevent TACO.
Figure 2. 
Pathophysiologic mechanisms in TRALI. This figure illustrates inflammatory processes in the lung both during 
the “first hit” and during the “second hit” (acute phase) where the inflammatory processes are heightened than 
the “first hit”. Mediators of inflammation in the infused blood products (FFP > platelets > RBCs) containing 
donor anti-granulocyte antibodies (anti-HLA and anti-HNA antibodies) along with cytokines and biologically 
active lipids activate inflammatory cascade through polymorph-nuclear cells (PMNs) with resultant capillary 
injury. As shown in the “second hit” section of the lung, the capillaries are congested, endothelial cells are swollen 
and inflamed, and there is increased platelet deposition and aggregation. The interstitial becomes more enlarged. 
There is increased adherence and migration of neutrophils of activated adhesion molecules (ICAM-1, P-Selectin, 
L-Selectin). Also, alveolar macrophages liberate inflammatory cytokines (IL-1b, IL-6, IL-8) and activated 
neutrophils elaborate PAF, NET compliments, and oxidant proteins. All these culminated in lung injury with 
noncardiogenic pulmonary edema causing hypoxemia, hypotension, pulmonary infiltrates, and fever.
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Managing
• Stop transfusion
• Position patient in upright position
• Supplementary oxygen
• Diuretics
• Cardiac and respiratory support as required
• Initiate transfusion reaction investigation
However, it is important to bear in mind the differences between TACO and 
TRALI (Table 4).
5.8 Allergic transfusion reactions
Allergic reactions following blood transfusions can be mild and frequently 
manifested by urticarial rash. Many urticarial reactions are donor-specific and thus 
do not occur with subsequent transfusion.
5.8.1 Management
If a recipient experiences multiple urticarial reactions, premedication with anti-
histamines should be considered.
Washed products re-suspended in albumin or saline may be considered in severe 
cases. While removing plasma through washing mitigates allergic reactions, washing 
platelets impair platelet functions and lead to accelerated clearance after transfusion.
Antihistamines generally alleviate symptoms of allergic reactions but have not 
been  proven to prevent them [7, 13].
5.8.2 Anaphylactic reaction
The incidence of anaphylactic reaction is put at 1 in 40,000 and the clinical 
presentation is characterized by widespread rash, shortness of breath cough, 
tachycardia, flushing, and anxiety.
Table 4. 
Differences between TRALI and TACO.
13
Blood Transfusion Reactions
DOI: http://dx.doi.org/10.5772/intechopen.85347
Severe IgA-deficient patients may make anti IgA antibody that can cause 
anaphylactic reaction, but this is a rare occurrence. Considering that approximately 
1 in 1200 people is IgA deficient with anti-IgA antibodies and that passively trans-
fused anti IgA antibodies do not cause allergic reactions, the pathophysiology of 
recurrent and severe allergic transfusion reactions in IgA deficiency is incompletely 
understood. Washed RBCs, washed platelets, and/or platelet and plasma products 
from IgA-deficient donors should be transfused only when a patient has severe IgA 
deficiency and a concern for anaphylactic reactions. Most IgA-deficient patients, 
even those with anti IgA, have no adverse reactions to transfusion. There are also 
reports of patients with deficiency of haptoglobin and various complement compo-
nents such as C4a (Rogers antigen) or C4b (Chido antigen) developing anaphylactic 
reactions to platelets [7, 13].
Management: as illustrated in Table 5 and Algorithm 1.
If hives/rash covers <25% of body stop transfusion; do the following: clerical 
check, notify physician, and notify blood bank.
If clerical error is identified or there are serious symptoms do not restart trans-
fusion, the following should be ensured:
1. Administer diphenhydramine 25–50 mg IV/po
2. Continue to monitor patient carefully and frequently
3. Stop transfusion if symptoms worsen or additional symptoms develop
4. If uneventful, complete transfusion reaction investigation form
5. No need to send blood samples or blood bag
6. Infectious complications
6.1 Approximate risk per transfused unit of various infectious agents
The risk per transfused units for each infectious agent is as shown in Table 6 [7].
Temp increase by >1°C and >38°C
1. Stop transfusion
2. Clerical check
3. Notify physician
4. Notify blood bank
Clerical error or additional serious symptoms?
No
Restart transfusion cautiously as ordered
Yes
Do not restart transfusion
1. Administer acetaminophen 325 mg
2. Continue to monitor patient carefully and 
frequently
3. Stop transfusion if symptoms worsen or 
additional symptoms develop
4. If uneventful, complete transfusion reaction 
investigation form
5. Send to blood bank with blood sample as per 
algorithm
1. Suspect hemolytic transfusion reaction or 
bacterial contamination
2. Initiate transfusion reaction investigation by 
completing form
3. Collect blood samples
4. Send blood bag to blood bank
5. Continue to monitor patient and report condi-
tion to physician
Table 5. 
The protocol to follow in the case of emergence of fever during blood transfusion.
Blood Groups
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6.2 Bacterial and parasitic transmissions by transfusion
In the United States, bacterial contamination of platelet products has been 
recognized as the most common cause of transfusion-associated morbidity and 
mortality owing to an infectious source. It exceeds hepatitis, HIV, and other viral 
sources put together. It was noted that the frequency of bacterial contamination 
is as high as 1 in 1000 to 1 in 2000 platelet units. It results in clinical sepsis after 
1 in 4000 platelet transfusions before preventive measures were put in place. As 
an example, the introduction of bacterial screening has reduced the risk of septic 
transfusion reactions for apheresis platelets, and it has declined to approximately 
1 in 75,000 with the risk of a fatal septic reaction declining to approximately 1 in 
500,000 [7, 14, 15].
Efforts to detect the presence of bacteria in platelet units before dispensing to 
a patient include incubating an aliquot of the unit in a culture system and using a 
rapid strip immunoassay for bacterial antigens. Other less sensitive methods for 
detection using a surrogate marker for evidence of bacterial metabolism, such as 
a low pH, in an aliquot of the platelet suspension have been discontinued. While 
platelet products are typically contaminated by Gram-positive cocci, such as 
coagulase-negative Staphylococci, sepsis associated with transfusion of RBC units is 
most often due to Gram-negative organisms, particularly Yersinia enterocolitica.
Red blood cell contamination with Yersinia enterocolitica had resulted in bacte-
remia and septic shock which is often catastrophic. This Gram-negative organism 
can survive during refrigerated storage and lead to bacteremia or septic shock in the 
transfused recipient. Malarial transmission by transfusion is very common in Africa 
where malaria is known to be endemic but uncommon in Europe and America but 
cases are occasionally reported [7, 15].
6.3 Hepatitis
The estimated risk of post-transfusion hepatitis C is 1 per 1.1 million units trans-
fused with current use of anti-hepatitis C virus antibody tests and nucleic acid testing.
Post transfusion hepatitis occasionally still develops despite the exclusive use of 
volunteer blood donors and screening of donor blood for hepatitis B and hepatitis 
C viruses. Transfusion-related hepatitis C virus infection is usually subclinical and 
anicteric in most cases but frequently becomes chronic and often results in clinically 
significant liver dysfunction [7, 15].
The risk of HBV transmission by transfusion decreased from 1:220,000 to 
approximately 1:750,000 after implementation of HBV DNA testing. Photochemical 
pathogen inactivation strategies appear both efficacious and relatively sparing in 
terms of qualitative platelet function, although decreases in quantitative platelet 
recovery have been observed in some studies [7, 15].
Infectious agent Approximate risk/transfused unit
Hepatitis B virus 1:750,000
Hepatitis C virus 1:1.1 million
HIV-1, HIV-2 1:2.7 million
Bacterial sepsis 1:75,000 (platelet transfusions)
Bacterial sepsis 1:250,000 to 1:10 million (red blood cell transfusions)
Table 6. 
Infectious complications of transfusion.
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6.4 HIV and human T-cell lymphotropic viruses
The risk of acquiring HIV-1 or HIV-2 infection as a result of transfusion cur-
rently is estimated to be 1 in 1.5 million. Nucleic acid amplification testing for HIV 
has reduced the window of serologic conversion from 16 days to about 9 days. The 
use of heat-treated concentrates, solvent detergent-treated products, and recom-
binant factor concentrates has essentially eliminated HIV as a therapy-risk for 
hemophiliacs [7, 15].
6.5 Human T-cell lymphotropic virus 1 (HTLV-1)
This is a retrovirus associated with adult T-cell leukemia or lymphoma and 
tropical spastic paraparesis. Screening for HTLV-1 in blood donors is currently 
performed in the United States because asymptomatic blood donors can transmit 
this virus. Several cases of neuropathy had been reported in transfused recipients 
before the availability of testing.
HTLV-2, a related virus with antigenic cross-reactivity to HTLV-1, is endemic in 
certain Native American populations and also has been found in a high proportion 
of intravenous drug users. The risk of HTLV transmission by transfusion using 
current test methods is approximately 1 in 2.7 million [7, 15].
6.6 West Nile virus (WNV)
WNV became known to the US during the 2002 (WNV) epidemic in the 
United States wherein 23 individuals acquired WNV after blood transfusion. 
The characteristic clinical features manifested include fever, confusion, and 
encephalitis which developed within days to weeks of transfusion. As a result, 
blood centers implemented nucleic acid-based testing to screen all donations  
for WNV.
In a survey of 2.5 million donations in 2003, 601 donations (0.02%) were found 
to contain WNV. A subsequent follow-up study detected no cases of transfusion-
transmitted WNV infection among recipients of tested blood; however, rare 
breakthrough transmissions have been reported [7, 15].
6.7 Parvovirus B19
Rare transmissions of parvovirus B19 by transfusion have been recognized. 
A recent study documented persistence of low levels of parvovirus B19 DNA in a 
high percentage of multi-transfused patients. The long-term clinical implications 
of this finding currently are unknown. Parvovirus (and other viruses without a 
lipid envelope such as hepatitis A virus) is not eliminated by solvent detergent 
treatment.
Acute parvovirus B19 infection can result in impaired erythropoiesis and can 
cause an aplastic crisis in patients with sickle cell disease and other hemolytic 
diseases. Infection with this virus can also result in significant fetal harm when a 
pregnant woman is infected during weeks 9–20 of pregnancy. There is no currently 
available blood donor screening assay for this virus [7, 15].
6.8 Cytomegalovirus (CMV)
CMV resides in leukocytes, and leukocytes inevitably contaminate RBC and 
platelet concentrate products. Hence, they are capable of transmitting CMV infection. 
Transfusion-transmitted CMV infection is an important issue in transfusion of cellular 
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blood products to neonates, particularly low-birth-weight infants born to seronegative 
mothers, HSCT recipients, and other highly immunosuppressed patients [7, 15].
The risk of acquiring CMV from transfusions is particularly high when pre-
transplantation serologic testing reveals that neither the HPSC donor nor the recipient 
has been previously exposed to CMV. In addition, transplantation recipients are at 
increased risk for transplantation-associated CMV reactivation when either the donor 
or the recipient is seropositive for CMV before transplantation. The latter consider-
ation often affects the choice of HPSC donors. For these reasons, some institutions use 
blood products obtained exclusively from CMV-seronegative donors when providing 
blood products to neonatal recipients or recipients of HPSC transplantations.
However, as noted earlier, a landmark randomized comparison of leukoreduced 
versus CMV-seronegative blood components in CMV-seronegative HSCT recipients 
(with seronegative donors) found no significant difference in the incidence of 
CMV infection, and CMV disease as a composite outcome and most transplantation 
centers [7, 15].
In practice, prestorage leukoreduced blood components will be used for CMV 
prevention. Other institutions simply use leukoreduced blood products in all recipi-
ents, regardless of CMV status. The latter strategy has the additional advantage 
of reducing the risk of alloimmunization to HLA antigens and thus of developing 
refractoriness to platelet transfusions.
6.9 Parasites
Malaria: malarial transmission by transfusion is common in malarial endemic 
regions of Africa. In nonmalarial endemic areas, donors with a history of residence 
in a malaria-endemic area or travel associated with a risk of malarial exposure are 
deferred for up to 3 years, depending on the exposure.
Chagas disease: Trypanosoma cruzi parasites can survive several weeks of 
storage in blood, and contamination of blood products with this organism is already 
a significant problem in parts of South America. Therefore, the immigration of 
individuals from South America to the United States raises concerns that Chagas 
disease may emerge as a common transfusion-transmitted infection [7, 15].
An FDA-approved blood donor-screening test for antibodies to T. cruzi is avail-
able. Blood donors only need to be tested at their first donation.
Babesiosis: this has been identified in receiving platelets, refrigerated RBCs, and 
even frozen-thawed RBCs. Cases have been reported in New England and the upper 
Midwest. Various tests are being evaluated for donor screening in areas endemic for 
Babesia [7, 15].
7. Conclusions
This chapter serves as a synopsis to adverse blood reactions which are very 
common but apparently more often under-recognized and/or under-reported 
particularly in developing countries. This should sharpen the consciousness of all 
health practitioners involved in blood transfusion services towards taking measures 
at preventing transfusion reactions right from donor selection up to the infusion of 
blood into the recipients.
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